Acromegaly Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Amolyt Pharma, Aquestive

Posted on
by

Acromegaly Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Amolyt Pharma, Aquestive
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acromegaly pipeline constitutes 15+ key companies continuously working towards developing 15+ Acromegaly treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acromegaly Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Acromegaly Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acromegaly Market.

 

Some of the key takeaways from the Acromegaly Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Acromegaly treatment therapies with a considerable amount of success over the years. 
  • Acromegaly companies working in the treatment market are OPKO Health, Amolyt Pharma, Aquestive Therapeutics, Rani Therapeutics, Glytech, Debiopharm International, Tiburio Therapeutics, Antisense Therapeutics, Ionis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Camurus AB, and others, are developing therapies for the Acromegaly treatment 
  • Emerging Acromegaly therapies in the different phases of clinical trials are- MOD-12014, AZP-3813, AQST-305, Octreotide-Ranipillcapsule, GT-02037, Debio 4126, TBR 065, ATL1103, IONIS-GHR-LRx, Paltusotine, CAM-2029, and others are expected to have a significant impact on the Acromegaly market in the coming years.  
  • In November 2021, MYRELEZ (lanreotide), the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumours, and symptoms associated with neuroendocrine tumours, was introduced in Norway by ADVANZ PHARMA, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe.
  • In September 2021, Following fruitful research collaboration between the two businesses, Amolyt Pharma and PeptiDream Inc. announced that Amolyt Pharma had exercised its option to globally licence a portfolio of macrocyclic peptide GHRAs. This was done in accordance with the terms of their research collaboration agreement to develop AZP-3813 as a potential treatment for acromegaly. For patients who do not satisfactorily respond to SSAs alone, the identified, optimised medication candidate, AZP-3813, is being explored as a potential treatment for acromegaly. It will be used in conjunction with SSAs.

 

Acromegaly Overview

Adults who have acromegaly experience a rare, gradually progressing acquired condition. It happens when the pituitary gland releases an excessive amount of growth hormone (GH). A small gland near the base of the skull called the pituitary gland is responsible for storing a number of hormones and releasing them into the bloodstream when the body requires them.

 

Get a Free Sample PDF Report to know more about Acromegaly Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acromegaly-pipeline-insight

 

Emerging Acromegaly Drugs Under Different Phases of Clinical Development Include:

  • MOD-12014: OPKO Health
  • AZP-3813: Amolyt Pharma
  • AQST-305: Aquestive Therapeutics
  • Octreotide-Ranipillcapsule: Rani Therapeutics
  • GT-02037: Glytech
  • Debio 4126: Debiopharm International
  • TBR 065: Tiburio Therapeutics
  • ATL1103: Antisense Therapeutics
  • IONIS-GHR-LRx: Ionis Pharmaceuticals
  • Paltusotine: Crinetics Pharmaceuticals Inc.
  • CAM-2029: Camurus AB

 

Acromegaly Route of Administration

Acromegaly pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Acromegaly Molecule Type

Acromegaly Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Acromegaly Pipeline Therapeutics Assessment

  • Acromegaly Assessment by Product Type
  • Acromegaly By Stage and Product Type
  • Acromegaly Assessment by Route of Administration
  • Acromegaly By Stage and Route of Administration
  • Acromegaly Assessment by Molecule Type
  • Acromegaly by Stage and Molecule Type

 

DelveInsight’s Acromegaly Report covers around 15+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Acromegaly product details are provided in the report. Download the Acromegaly pipeline report to learn more about the emerging Acromegaly therapies

 

Some of the key companies in the Acromegaly Therapeutics Market include:

Key companies developing therapies for Acromegaly are – Pfizer Inc, Novartis AG, Validus Pharmaceuticals LLC, Ipsen, Chiasma, Inc, Crinetics Pharmaceuticals, Ionis Pharmaceuticals Inc, Midatech Pharma Plc, ADVANZ PHARMA, Amolyt Pharma, and others.

 

Acromegaly Pipeline Analysis:

The Acromegaly pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Acromegaly with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acromegaly Treatment.
  • Acromegaly key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Acromegaly Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acromegaly market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Acromegaly drugs and therapies

 

Acromegaly Pipeline Market Drivers

  • Increasing incidence of pituitary tumors and acromegaly, favorable government insurance policies and schemes are some of the important factors that are fueling the Acromegaly Market.

 

Acromegaly Pipeline Market Barriers 

  • However, high cost of treatment, lack of awareness and patient education and other factors are creating obstacles in the Acromegaly Market growth.

 

Scope of Acromegaly Pipeline Drug Insight    

  • Coverage: Global
  • Key Acromegaly Companies: OPKO Health, Amolyt Pharma, Aquestive Therapeutics, Rani Therapeutics, Glytech, Debiopharm International, Tiburio Therapeutics, Antisense Therapeutics, Ionis Pharmaceuticals, Crinetics Pharmaceuticals Inc., Camurus AB, and others
  • Key Acromegaly Therapies: MOD-12014, AZP-3813, AQST-305, Octreotide-Ranipillcapsule, GT-02037, Debio 4126, TBR 065, ATL1103, IONIS-GHR-LRx, Paltusotine, CAM-2029, and others
  • Acromegaly Therapeutic Assessment: Acromegaly current marketed and Acromegaly emerging therapies
  • Acromegaly Market Dynamics: Acromegaly market drivers and Acromegaly market barriers 

 

Request for Sample PDF Report for Acromegaly Pipeline Assessment and clinical trials

 

Table of Contents 

1. Acromegaly Report Introduction

2. Acromegaly Executive Summary

3. Acromegaly Overview

4. Acromegaly- Analytical Perspective In-depth Commercial Assessment

5. Acromegaly Pipeline Therapeutics

6. Acromegaly Late Stage Products (Phase II/III)

7. Acromegaly Mid Stage Products (Phase II)

8. Acromegaly Early Stage Products (Phase I)

9. Acromegaly Preclinical Stage Products

10. Acromegaly Therapeutics Assessment

11. Acromegaly Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acromegaly Key Companies

14. Acromegaly Key Products

15. Acromegaly Unmet Needs

16 . Acromegaly Market Drivers and Barriers

17. Acromegaly Future Perspectives and Conclusion

18. Acromegaly Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services